Fig. 5
LPS enhances the tumorigenicity of SGC7901 cells via the TLR4/MD-2 pathway. a and b: SGC7901 cells (2 × 106 cells/mice) treated with different shRNAs (sh-NC, sh-TLR4 and sh-MD-2) were injected subcutaneously into the flanks of nude mice, and the mice were intratumorally injected with LPS (400 μg/kg) every other day. The tumor volume was observed (a) and measured (b); *, P < 0.05. The data are presented as the mean ± SD; C: CXCR7 expression in tumors was analyzed via immunohistochemistry (original magnification 400×)